Company Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally.
The company’s lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus.
It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia.
Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jul 23, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 147 |
| CEO | Rachel Haurwitz |
Contact Details
Address: 2929 7th Street, Suite 105 Berkeley, California 94710 United States | |
| Phone | 510 982 6030 |
| Website | cariboubio.com |
Stock Details
| Ticker Symbol | CRBU |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001619856 |
| CUSIP Number | 142038108 |
| ISIN Number | US1420381089 |
| Employer ID | 45-3728228 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Timothy P. Kelly M.B.A. | Chief Technology Officer |
| Dr. Steven B. Kanner Ph.D. | Chief Scientific Officer |
| Barbara G. McClung Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Sriram Ryali M.B.A. | Chief Financial Officer |
| Daniel Poon | Vice President of Operations and Information Technology |
| Ryan Fischesser | Interim Principal Accounting Officer and Controller |
| Amy Figueroa C.F.A. | Vice President of Investor Relations and Corporate Communications |
| Reigin Zawadzki | Chief People Officer |
| Ruhi A. Khan M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2025 | SCHEDULE 13G/A | Filing |
| Jun 23, 2025 | 8-K | Current Report |
| Jun 13, 2025 | 8-K | Current Report |
| May 14, 2025 | EFFECT | Notice of Effectiveness |
| May 12, 2025 | UPLOAD | Filing |
| May 8, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 8, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 30, 2025 | SCHEDULE 13G/A | Filing |